Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average Target Price from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.38.

TSHA has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Needham & Company LLC lowered their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Canaccord Genuity Group dropped their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. BMO Capital Markets started coverage on shares of Taysha Gene Therapies in a research note on Thursday, June 27th. They set an “outperform” rating and a $5.00 target price for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, June 20th.

Taysha Gene Therapies Trading Up 1.9 %

Taysha Gene Therapies stock opened at $2.19 on Tuesday. Taysha Gene Therapies has a 1 year low of $1.27 and a 1 year high of $4.32. The firm’s 50-day moving average is $2.21 and its 200-day moving average is $2.60. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.22 and a current ratio of 5.22. The company has a market cap of $448.82 million, a P/E ratio of -4.47 and a beta of 0.41.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $3.62 million. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. During the same quarter last year, the company posted ($0.38) earnings per share. On average, equities analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Activity at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning bought 1,333,333 shares of the business’s stock in a transaction on Thursday, June 27th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $2,999,999.25. Following the completion of the transaction, the insider now directly owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. acquired a new position in Taysha Gene Therapies in the fourth quarter worth approximately $28,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $31,000. Avoro Capital Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 11.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock valued at $7,709,000 after purchasing an additional 430,555 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Taysha Gene Therapies in the 4th quarter valued at $370,000. Finally, Chicago Partners Investment Group LLC boosted its position in shares of Taysha Gene Therapies by 21.4% in the 4th quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock valued at $239,000 after purchasing an additional 23,740 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.